about
Prevention of infections during primary immunodeficiencyEvaluation of BC-3 and BCP-1 cell lines in immunofluorescence assay to detect HHV-8 antibodies in Kaposi's sarcoma, multiple myeloma and other groups.[Diabetes insipidus revealing primary malignant non-Hodgkin's lymphoma of bone].Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.Denosumab for treatment of hypercalcemia of malignancy.Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients.Cardiac amyloidosis: updates in diagnosis and management.Infections in 252 patients with common variable immunodeficiency.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series.Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Al amyloidosisImpact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaL-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.Extranodal natural killer/T-cell lymphoma: advances in the management.18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature review.Neuroarthropathy of the foot revealing primary systemic amyloidosis: case report and literature review.Clonal deleted latent membrane protein 1 variants of Epstein-Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment.Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes.Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein.Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy.Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.Hepatocyte growth factor measurement in AL amyloidosis.Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells.Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival.Aggressive systemic mastocytosis.New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis.Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
P50
Q27008430-27B8C978-9B5A-4A00-BEB7-F84DDDAE2ADAQ30724383-6FE7A3EE-BFA6-4620-B730-68909E3F8F74Q31947918-53D77DA2-FADE-41F6-8CC8-CE2B6B506FABQ33404104-99F56621-F674-4280-8A3C-0F346ABE0A8BQ33430928-8923C49E-3367-48BE-9009-1BF4F21137EFQ33456341-F3DF7C87-2361-48E1-AB29-394748D57B1CQ34130902-E074BEAA-0454-4886-8C89-8B9EF41FAB11Q34300297-3151315C-4327-485F-B3C4-3203C141C9C3Q34373589-F9AFE16D-91AD-4C39-B935-643FFD5D2644Q34590662-68685FC8-B440-4992-82A7-E72D78D6A04FQ36036322-ED4BC74C-E9F1-4E4C-BB84-2C58FE5C8285Q36151870-A6E53192-4EA0-4332-8D71-67FEF315E81FQ36382187-81A9F1FF-C88D-433F-8B1A-0F67BD886EA9Q36392233-544921CB-FBAD-486D-8BB4-E75198ED8450Q36750472-A9A5AE90-2AE8-4D1A-A271-83BE3DBB203AQ37243101-5F6A71E5-6890-4546-9A70-6388A5678704Q37371179-3294BE3F-6F58-4A77-82CE-47584EB3705DQ37899728-96FBEB5C-97B5-4059-8BB3-BE5EAC695942Q38010222-E8748266-3D39-493F-852F-6AFEE8A1A228Q38250214-248A8986-59A4-41B6-B1C9-6FEEFCEF0539Q38779524-51169E6F-FAB7-469E-8849-D74594504161Q39251679-C21BBC12-77F8-46DD-9A0A-86C09895DB40Q39653060-2506B3BB-53E2-44D0-A6F9-C801F825FEE5Q39692801-0B0A03B0-E96C-4965-A1D1-58661458F2C2Q39821908-2F995E0E-F3BC-4A8B-98F0-39DD4D212B3FQ39999898-900EE3A4-2DDC-4F8B-81FA-6F2CFD01ABE2Q40691286-9D94CA4D-141F-479A-8DDB-98B0E66295C9Q40705462-4905AE82-3FE9-43E4-94A0-88F583EAA02CQ40806698-B9829749-BAD4-470E-BB3A-6D0F68DE0E71Q40859702-43155801-D7A1-4A3E-B780-F534F2D982E8Q40925953-A4AC09E3-B61B-4C7A-AE70-8AD305FB049EQ41139081-415703E1-C173-4431-8A0B-0536ED0DB986Q42628866-C97507AE-5E65-4725-B918-51E8F679D6E3Q42931881-A0092006-4295-4341-9579-A3CD57268484Q43498163-F657EE36-93D6-4A36-A278-0AACF46A344DQ44052238-6CBBB428-A5D8-45C9-9619-170AFFD34B58Q44363705-AE9D14B9-75C0-4E91-9F22-9E2E5AC95363Q44572498-0E7DEFD0-A23A-41A8-92BD-27AFEE279D94Q44573292-DD0A2D9E-9F8D-4E97-BD54-0C61BDB9F5D5Q45069595-24402058-F486-491A-BCB0-799E488BD910
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Arnaud Jaccard
@ast
Arnaud Jaccard
@en
Arnaud Jaccard
@es
Arnaud Jaccard
@nl
type
label
Arnaud Jaccard
@ast
Arnaud Jaccard
@en
Arnaud Jaccard
@es
Arnaud Jaccard
@nl
prefLabel
Arnaud Jaccard
@ast
Arnaud Jaccard
@en
Arnaud Jaccard
@es
Arnaud Jaccard
@nl
P1053
O-8819-2016
P106
P1153
7003722388
P21
P31
P3829
P496
0000-0001-7091-8253